Curis | CRIS - Ebitda


Curis reported $-12.3M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Amgen USD 3.86B 1.28B Mar/2026
AstraZeneca USD 5.16B 510M Jun/2026
Bayer EUR 2.14B 2.31B Jun/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Curis USD -12.3M 231K Sep/2023
Eli Lilly USD 10.29B 1.86B Mar/2026
Exelixis USD 255.4M 2.89M Jun/2026
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Incyte USD 778.57M 410.6M Jun/2026
Merck USD -1.54B 7.84B Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Pfizer USD 6.01B 18M Jun/2026
Roche Holding CHF 13.43B 744M Jun/2026
Sanofi EUR 3.69B 375M Jun/2026
Takeda JPY 364.46B 214.21B Jun/2026
TG Therapeutics USD 26.9M 1.21M Jun/2026